Richard A. Md Miller Purchases 577,634 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Richard A. Md Miller acquired 577,634 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The shares were acquired at an average cost of $1.73 per share, with a total value of $999,306.82. Following the purchase, the chief executive officer now owns 577,634 shares in the company, valued at approximately $999,306.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ CRVS opened at $1.68 on Wednesday. The company has a 50 day simple moving average of $1.78 and a 200-day simple moving average of $1.78. The company has a market capitalization of $82.39 million, a P/E ratio of -2.95 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 1 year low of $1.05 and a 1 year high of $4.19.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14). As a group, research analysts expect that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current year.

Wall Street Analyst Weigh In

CRVS has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Oppenheimer upped their price objective on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Mizuho reaffirmed a “neutral” rating and set a $3.50 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th.

Institutional Trading of Corvus Pharmaceuticals

A hedge fund recently raised its stake in Corvus Pharmaceuticals stock. Towerview LLC lifted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 27.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 436,873 shares of the company’s stock after buying an additional 94,395 shares during the period. Corvus Pharmaceuticals makes up approximately 0.5% of Towerview LLC’s portfolio, making the stock its 17th largest position. Towerview LLC owned about 0.89% of Corvus Pharmaceuticals worth $769,000 at the end of the most recent quarter. 46.64% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.